Camille Houy

Ms. Camille Houy

Sanofi, Toronto, Ontario, Canada
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Biologicals
Verified
Journal Article
Open access
MSMartha Erika Navarro Sanchez
Martha Erika Navarro Sanchez
NDNicolas Devard
Nicolas Devard
CHCamille Houy
Camille Houy
EAEric Abachin
Eric Abachin
SGSabine Godard
Sabine Godard
NNNolwenn Nougarede
Nolwenn Nougarede

13 May 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
CHCamille Houy
Camille Houy
MMMarin Ming
Marin Ming
LELuciano Ettorre
Luciano Ettorre
RJRobbie Jin
Robbie Jin
NTNemika Thangavadivel
Nemika Thangavadivel
BGBeata Gajewska
Beata Gajewska
In the vaccine industry, multiple physicochemical, immunological, in vitro and in vivo analytical methods are applied throughout the manufacturing process to characterize and monitor the quality of vaccines. Presented here is the Single Epitope Antigenicity Test (SEAT), an innovative, quantitative epitope profiling method which provides an extended immunochemical analysis for diphtheria toxoid (DTxd) to be used for consistency testing during manufacturing process changes. The method uses BioLayer Interferometry (BLI) and a panel of monoclonal antibodies (mAbs) to independently assess nine individual antigenic sites of DTxd. The panel includes mAbs which are functional, bind distinct sites on DTxd and are able to distinguish intact DTxd from that which has been exposed to heat treatment. The SEAT method was qualified for precision, accuracy, and linearity, and was used to define a preliminary comparability range for DTxd made using the current manufacturing process. DTxd lots manufactured using alternate processes were assessed in the context of this range to determine the impact on DTxd antigenicity. Epitope profiling by SEAT provides quantitative information on the integrity of multiple important antigenic regions of DTxd, and therefore represents a valuable tool in a comprehensive analytical test package which can be used to support manufacturing process changes for vaccines.

26 July 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
LELuciano Ettorre
Luciano Ettorre
TWTrevor Williams
Trevor Williams
CHCamille Houy
Camille Houy
SZShaolong Zhu
Shaolong Zhu
MKMichael Kishko
Michael Kishko
JSJason Szeto
Jason Szeto
Background/Objectives: An initial COVID-19 candidate vaccine containing a purified ancestral SARS-CoV-2 spike antigen was characterized with an ELISA using recombinant monoclonal antibodies (mAbs) generated against this variant. Upon the emergence of a new Beta (B.1.351) spike variant early in the pandemic, the assessment of a bivalent vaccine containing ancestral and Beta spike antigens began. Due to accelerated project timelines, mAbs generated specifically against the Beta spike antigen were not available at the time to address assay development and vaccine testing requirements. Methods: Using only the initial mAb panel raised against the ancestral spike antigen, an epitope-blocking ELISA strategy was developed to independently measure Beta spike antigen in bivalent vaccine formulations. To facilitate this, epitope profiling of spike antigens from both ancestral and Beta variants was performed with biolayer interferometry and hydrogen–deuterium exchange mass spectrometry using the original panel of mAbs. Results: The resulting blocking ELISA was precise and specific for the Beta spike antigen and detected the expected amount of this antigen in bivalent vaccine formulations. The specific amount of ancestral spike protein in the bivalent vaccine was also confirmed using the original ELISA developed at the onset of the pandemic. Conclusions: This epitope-blocking strategy helped to overcome key reagent availability issues and could be applied to other projects involving related proteins.